logo
Sebi flags expiry-day derivatives surge as retail losses top ₹1 trillion

Sebi flags expiry-day derivatives surge as retail losses top ₹1 trillion

Mint3 days ago
Mumbai: A senior official at India's markets regulator has raised red flags over the surge in short-term equity derivatives trading, particularly expiry-day index options, warning that the current structure may be unsustainable and detrimental to long-term capital formation.
The Securities and Exchange Board of India (Sebi) has been closely tracking the exponential rise in such activity, which has been accompanied by significant losses for retail investors. At the 11th Capital Markets Conclave of Confederation of Indian Industry (CII) in Kolkata on Thursday, Sebi's whole-time member Ananth Narayan G said the regulator is focused on balancing innovation with investor protection.
'There is no question that derivatives and indeed, speculation are vital for price discovery, hedging, and ensuring market depth. But certain trends in our equity derivatives ecosystem have warranted a closer look for a while now,' Narayan told the gathering.
He flagged a stark imbalance in market activity: 'On expiry days, comparable turnover in index options is often 350 times or more the turnover in the underlying cash market—an imbalance that is obviously unhealthy, with several potential adverse consequences.'
Narayan cited Sebi's latest research report, released on 7 July, which found that 91% of individual traders incurred net losses trading in futures and options (F&O) in FY25, with total losses exceeding ₹ 1 trillion. 'This is a large sum of money that could have otherwise gone towards responsible investing and capital formation,' he said.
The regulatory focus on expiry-day option trading comes in the wake of Sebi's recent action against US-based quant trading firm Jane Street.
On 3 July, Sebi barred the firm from accessing the securities market for deploying what it described as manipulative trading strategies around index options expiry, directing it to deposit ₹ 4,800 crore—the alleged unlawful gains—into a Sebi escrow account.
Jane Street has since complied with the directive, paving the way for a potential resumption of trading in India, subject to Sebi's review. The regulator is currently assessing the firm's request.
While Narayan did not refer to Jane Street by name, his remarks appeared to echo broader regulatory concerns: 'noise trading that may potentially undermine confidence in price formation' and 'unhealthy' market structures.
Narayan also drew attention to possible conflicts of interest: 'We recognize the potential concerns of market infrastructure institutions, brokers, and other intermediaries, whose revenues may depend heavily on these short-term derivative volumes. But we must ask ourselves collectively – is all this at all sustainable?'
Sebi has introduced a series of regulatory measures since October 2024 aimed at tempering speculative excesses. 'We are seeing some signs of moderation of the trends noted above. However, this specialized area requires ongoing constructive debate and work,' Narayan said.
That October, the regulator reduced the frequency of weekly expiries, increased contract lot sizes, scrapped calendar spread benefits on expiry day, implemented intraday position checks, mandated upfront collection of option premia, and raised extreme loss margins on expiry days.
In May 2025, Sebi followed up with measures to improve risk metrics and disclosures in F&O, reduce instances of spurious F&O ban periods in single stocks, and strengthen oversight of index options to mitigate potential concentration or manipulation risks.
Fresh data from Sebi's 7 July study, based on individual trading activity between December 2024 and May 2025, shows early signs of cooling. In FY25, turnover by individual investors in index options declined 9% year-on-year in premium terms and 29% in notional terms. The number of unique retail participants in the derivatives market also fell 20% from last year's record highs, suggesting a slowdown in the speculative frenzy that had drawn millions of new entrants.
Looking ahead, Narayan called for deeper market engagement: 'We must look for further ways to further deepen our cash equities markets, even as we look to improve the quality of our derivatives market by extending the tenure and maturity of the products and solutions on offer.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AU Bank profit rises 16% to 581 cr in Apr-June qtr
AU Bank profit rises 16% to 581 cr in Apr-June qtr

Time of India

time2 hours ago

  • Time of India

AU Bank profit rises 16% to 581 cr in Apr-June qtr

Jaipur: AU Small Finance Bank posted a 16% growth in net profit to Rs 581 crore during the first quarter of this financial year. The Jaipur-based bank had earned a net profit of Rs 503 crore in the same quarter of the previous fiscal year. Tired of too many ads? go ad free now The total income rose to Rs 5,189 crore during the June 2025 quarter from Rs 4,278 crore in the same period of FY25, AU Small Finance Bank said in a regulatory filing. Interest earned by the bank improved to Rs 4,378 crore compared to Rs 3,769 crore in the June quarter of FY25. Net interest income rose to Rs 2,045 crore during the quarter against Rs 1,921 crore a year ago. The bank's operating profit also increased to Rs 1,312 crore from Rs 952 crore in the year-ago period. Gross loan portfolio (GLP) grew 18% to Rs 1,17,624 crore compared to Rs 99,792 crore as of Q1 FY25, it said. Similarly, net NPAs, or bad loans, increased to 0.88% against 0.63% in the year-ago period. As a result, provisions and contingencies almost doubled to Rs 533 crore during the first quarter compared to Rs 283 crore a year ago. Provision Coverage Ratio (PCR) stood at 83% at the end of June 2025. However, the capital adequacy ratio of the bank declined to 19.42 per cent from 20.11 per cent in the same quarter of FY25. Commenting on quarterly numbers, AU Small Finance Bank MD and CEO Sanjay Agarwal said, "We have reported another set of consistent performance in a seasonally soft quarter, showing sustainable growth in deposits, assets, and profitability". As the economic cycle strengthens, AU is well-positioned to navigate near-term uncertainties while staying committed to the long-term vision of building a forever bank that can truly scale with sustainability,headded.

Zydus Life's plans for cancer biosimilar hit a legal hurdle
Zydus Life's plans for cancer biosimilar hit a legal hurdle

Time of India

time2 hours ago

  • Time of India

Zydus Life's plans for cancer biosimilar hit a legal hurdle

Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Mumbai: The Delhi High Court has issued an interim injunction against Ahmedabad-based drug maker Zydus Lifesciences after a case filed by the US pharma giant Bristol Myers Squibb alleging patent infringement on its blockbuster anticancer drug Opdyta nivolumab ) branded as Opdivo in other restraining order comes as a setback for the Indian drug maker which was running clinical trials in India for the launch of the biosimilar versions of nivolumab. The earliest patent for the drug expires in India on May 2, 2026. The next hearing for the case is August 101-page order issued on July 18 by Justice Mini Pushkarna ruled that the defendants, and all others acting on its behalf, are restrained from manufacturing, using, selling, offering for sale, importing, exporting, advertising, or dealing in any biosimilar/similar biologic of nivolumab, the suit patent, during the pendency of the present suit. The order stated the plaintiffs shall suffer irreparable loss, in case the interim relief as prayed for, was not injections are one of the many latest generation immunotherapy drugs also known as checkpoint inhibitors increasingly used to treat several types of cancers including skin, lungs, kidneys, and Hodgkin lymphoma. It works by activating the body's T-cells or immune cells by targeting a protein called PD-1, thereby unleashing an attack on the cancer vials are sold in India for roughly '2 lakh but for patients who are part of the company's assistance or access programs, the drug is available at a slab-wise discounted the India data is not available, globally Bristol Myers Squibb recorded Opdivo sales of $9.3 billion in 2024. Indian companies have launched biosimilars at half the cost of those charged by their global in Indian patent laws told ET that the court has taken a view that stockpiling of a product during its active patent life amounts to infringement and to release it or flood the market is not legally valid."This opinion may have implications for the other ongoing disputes like the weight-loss drug semaglutide (branded Wegovy) case between Novo Nordisk and Dr. Reddy's Labs or Roche versus Natco for Risdiplam (drug used for a rare disease called spinal muscular atrophy or SMA) case," a senior lawyer petition from BMS noted that Zydus Lifesciences was conducting clinical trials for nivolumab and on its investigation found that the company had plans to launch it during the patent period. The Indian company, it said, had applied for a marketing approval with the central drug regulatory its part, lawyers on behalf of Zydus defended saying its product ZRC-3276 does not infringe upon the existing patents and is following the regulatory was represented by a battery of top lawyers including Harish Salve, Dushyant Dave, and Rajiv Nayar, while Squibb & Sons was represented by Sandeep Sethi, PS Raman, Amit Sibal and Pravin Anand, among others.

Trump-Xi meet likely in Shanghai or on the sidelines of Apec summit in South Korea: Report
Trump-Xi meet likely in Shanghai or on the sidelines of Apec summit in South Korea: Report

First Post

time3 hours ago

  • First Post

Trump-Xi meet likely in Shanghai or on the sidelines of Apec summit in South Korea: Report

This month, Chinese Foreign Minister Wang Yi and US Secretary of State Marco Rubio met face-to-face, a step toward a potential leaders' summit. read more The Asia-Pacific Economic Cooperation (Apec) summit in South Korea, set for October 30 to November 1, offers a key opportunity for Chinese President Xi Jinping and his US counterpart Donald Trump to meet, South China Morning Post (SCMP) reported, citing sources. Trump might visit China beforehand or meet Xi on the sidelines of the Apec event in Gyeongju, where Xi plans to attend, though Trump's participation is unconfirmed, the Hong Kong based outlet reported. STORY CONTINUES BELOW THIS AD This month, Chinese Foreign Minister Wang Yi and US Secretary of State Marco Rubio met face-to-face, a step toward a potential leaders' summit. Last month, Xi invited Trump and his wife to China, an invitation Trump reciprocated. Rubio noted a 'strong desire on both sides' for a presidents' meeting. US-China relations have been rocky since Trump's January return to the White House, as the US leader issued threats of imposing 145 per cent tariffs on Chinese goods. Both sides have since worked on stabilising ties, reaching a preliminary trade deal easing China's rare-earth export restrictions and US technology trade barriers. Analysts suggest a pre-Apec meeting in China, possibly in Shanghai, is likely to differentiate from Trump's 2017 Beijing visit. Diao Daming of Renmin University was quoted by SCMP as saying: 'Under favourable conditions and an appropriate atmosphere, any form of interaction between the two leaders will aid in the stabilisation and development of US-China relations.' Bonnie Glaser of the German Marshall Fund noted that China sees a summit as stabilising. 'They maintain that a leaders' meeting could create greater stability in the relationship,' she said, adding it could allow Xi to push for eased technology restrictions and the US reaffirmation against Taiwan independence. Beijing views Taiwan as its territory, to be reunited if necessary by force. The US, while not recognising Taiwan's independence, opposes forceful takeover and is obligated to arm Taiwan. STORY CONTINUES BELOW THIS AD Sun Chenghao of Tsinghua University said a summit could break deadlocks on issues like fentanyl and tariffs: 'If certain issues can be clarified directly through a summit between the two leaders, I believe we could see relatively swift breakthroughs in specific areas of US-China relations.' Chen Qi of Tsinghua added: 'Both sides are indeed working to create a conducive atmosphere for a meeting.' Cooperation on trade and export controls could foster positive interactions. Observers note that Trump's greater eagerness gives Beijing leverage. 'It's up to China. Trump would be on a plane to Beijing tomorrow if he could,' said Jeremy Chan of Eurasia Group. 'China is very protocol driven and wants all agreements lined up well in advance while Trump would be happy to hash it all out over a Big Mac.' However, Taiwan or hawkish US actions could derail plans. 'The summit will be well telegraphed in advance,' Chan said. 'But all it would take would be one slip up along the way to derail the whole thing.' STORY CONTINUES BELOW THIS AD

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store